Several patients have come to our clinic after receiving additional bFGF injections of PRP, but they ended up with tumescent scars and were in a miserable state. The manufacturer has also notified that off-label use is absolutely prohibited, but since it is a drug that is not a reagent, any trouble caused by off-label use could cause harm not only to the patient but also to the manufacturer. However, the number of cases, over 9, is impressive. They must have built up know-how.

Personally, I feel that there are a considerable number of people suffering from exosome infusion damage that have not yet come to light.

There is a group of cosmetic surgery clinics that have openly presented at academic conferences the treatment method used in this lawsuit, which involves mixing Fiblast Spray into PRP and administering it, and this news came just when we thought it was inevitable that this would become a societal issue.

There are many cosmetic medical treatments that lack evidence and are driven primarily by profit.

I hope that cosmetic medical treatment will be cleansed and people will no longer be so critical of it.